NEW YORK – The latest approval of niraparib (GlaxoSmithKline's Zejula) for heavily pretreated ovarian cancer patients with homologous recombination deficiency (HRD) not only increases the number of patients eligible for the drug, but also adds another biomarker that oncologists can use to help them decide whether to prescribe this PARP inhibitor or another drug.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.